AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02214147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib will be supplied as enteric coated tablets.
Study NCT00354224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT00354224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT02361567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramacet
Description: Pain medication commonly used post-operatively
Study NCT02361567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Percocet
Description: Pain medication commonly used post-operatively
Study NCT02247349 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986012 (anti-fucosyl-GM1)
Study NCT04480502 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: PD-L1 single domain antibody for subcutaneous injection.
Study NCT04480502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: CTLA-4 monoclonal antibody
Study NCT00609115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMES device (test)
Description: Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.
Study NCT00609115 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AMES device (sham)
Description: Eighteen treatment sessions for each qualifying subject limb using the AMES device (sham) in which the limb is moved, but no active assistance is provided by the subject and the vibration is delivered at a very low frequency to the shortening (i.e., rather than lengthening) muscle. Each treatment session to provide thirty minutes of the placebo form of AMES therapy.
Study NCT00609115 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AMES device (crossover)
Description: Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed as soon as possible after the completion of Arm C-1 Sham Comparator.
Study NCT02248428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: 500mg orally daily on days 1-28,repeated every 28 days
Study NCT02248428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide 100-200mg orally per night on days 1-28,repeated every 28 days
Study NCT02248428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Thalidomide 100-200mg orally per night on days 1-28,repeated every 28 days
Study NCT02248428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300mg/m\^2 intravenously daily on day 1-3,repeated every 28 days
Study NCT02248428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 300mg/m\^2 intravenously daily on day 1-3,repeated every 28 days
Study NCT02248428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg orally weekly on days 1,8,15,22,repeated every 28 days
Study NCT02248428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 40 mg orally weekly on days 1,8,15,22,repeated every 28 days
Study NCT03254407 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Screening medical record
Description: Communicating possible IV/PO switch to prescriber by phone or e-note in medical record
Study NCT02682069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MolecuLight i:X Imaging Device
Description: The intended use of the device is to assist clinicians during care and management of patients with chronic wounds by screening for the presence of potentially harmful bacteria levels. The device will be used as part of the current clinical wound assessment process which may include examination for characteristic signs and symptoms of infection. The device can capture and document either an image or video of the chronic wound where the presence of florescent bacteria appears under violet light illumination. This information can be used to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present.
Study NCT00755573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin 300 mg - 600 mg BID
Study NCT00755573 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Regime as described for pregabalin
Study NCT02247349 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT01799356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: daily 400 mg moksifloksasin
Study NCT01799356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ofloxacin
Description: daily 800 mg oflaksasin plus 1000 mg metronidazol treatment
Study NCT01799356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metronidazole
Description: daily 1000 mg metronidazol plus 800 mg oflaksasin treatment for uPID
Study NCT04296812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Love Model
Description: The model is a visual illustration shaped as a triangle.~* The bottom left line is title Zero Self-Love, moving upward are characteristics identified from zero self-love along the line.~* The bottom right side is titled Self-Love moving upward are characteristics identified from having self-love.~* At the top of the triangle is a circle with the letter R within for relationship.~* Two small lines project horizontally, from the circle, left and right.~* At the end of the Left line is a circle with the word break-up in the middle, surrounded by terms: drugs, alcohol, self-harming, suicide, and sex as the consequence of zero self-love.~* At the end of right line is a circle with the word break-up in the middle surrounded by terms: support system, coping skills, spirituality reflection as the consequences of having self-love.~The strategies being discussed:~* Exploring self-esteem strategies.~* Importance of self-worth in relationships.~* Importance of self-awareness.
Study NCT02138851 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ficus Carica (300g/day)
Description: Ficus Carica (300g/day), parallel design
Study NCT02138851 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (300g/day)
Description: Placebo (300g/day), parallel design
Study NCT01410097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Intensive Lifestyle Intervention that includes diet, physical activity, and behavior modification. The goal of the ILI intervention was for individuals to achieve and maintain a loss of at least 7% of initial body weight.
Study NCT01410097 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Diabetes Support Education
Description: It offers an educational program to participants including developing support groups. Providing such benefits helps retain these participants in the trial.
Study NCT02383017 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Shroom Tech Sport
Description: STS will be given every day in accordance to company guidelines for 12 weeks.
Study NCT02383017 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given in the same fashion as the STS pills guidelines for 12 weeks.
Study NCT00683865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofloxacin
Description: Ofloxacin 400 mg po bid plus metronidazole 500 mg po bid for 14 days
Study NCT00683865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelox (Moxifloxacin, BAY12-8039)
Description: Moxifloxacin 400 mg po od for 14 days
Study NCT01446341 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Below knee plaster casting
Description: Subjects will be randomly assigned to either immobilization of their lateral ankle sprain with a below knee cast or to enter a functional rehabilitation program
Study NCT01446341 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional rehabilitation
Description: Subjects will be randomly assigned to either immobilization of their lateral ankle sprain with a below knee cast or to enter a functional rehabilitation program
Study NCT00516659 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Heat-Labile Enterotoxin of Escherichia coli (LT)
Description: Subjects in Group 1 will receive two vaccinations of a patch containing 37.5µg LT 2 to 3 weeks apart.
Study NCT00516659 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo patch contains all of the components of the active patch, but with no LT included in the formulation.
Study NCT04358081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ
Description: Hydroxychloroquine Monotherapy
Study NCT04358081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ+AZT
Description: Hydroxychloroquine with azithromycin
Study NCT04358081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02530502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02530502 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02530502 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo focal RT
Study NCT02530502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT04601766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-1202+APL-1501 ER Tablets 3+APL-1501 ER Tablets 2
Description: Phase1: Period 1 drug administration( APL-1202 50 mg, 3 tablets, orally );Washout( 7± 1 day) ; Period 2 drug administration(1501 ER Tablets 3 382 mg ASN-1324, 1 tablet); Phase2:Washout(The initiation of second phase will depend on the results of first phase within 30 days and not less than 7 days after the first phase ); Period 3 (APL-1501 ER Tablets 2,382 mg ASN-1324, 1 tablet)
Study NCT04601766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-1501 ER Tablets 3+APL-1202+APL-1501 ER Tablets 2
Description: Phase1: Period 1 drug administration( 1501 ER Tablets 3 382 mg ASN-1324, 1 tablet );Washout( 7± 1 day) ; Period 2 drug administration(APL-1202 50 mg, 3 tablets, orally); Phase2:Washout(The initiation of second phase will depend on the results of first phase within 30 days and not less than 7 days after the first phase ); Period 3 (APL-1501 ER Tablets 2,382 mg ASN-1324, 1 tablet)
Study NCT03591874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Tartrate
Description: Brimonidine Tartrate Nanoemulsion Eye Drops given 2 times a day for 12 weeks.
Study NCT03591874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Opthalmic buffered saline solution Eye Drops given 2 times a day for 12 weeks.
Study NCT03390608 — intervention group
Intervention type: DRUG
Intervention: Endocrine therapy
Description: Endocrine treatment versus no endocrine therapy (in women with hormone receptor positive1 disease).
Study NCT03390608 — intervention group
Intervention type: RADIATION
Intervention: Radiotherapy
Description: Radiotherapy versus no radiotherapy.
Study NCT03390608 — intervention group
Intervention type: DRUG
Intervention: Herceptin
Description: Trastuzumab versus no trastuzumab (in women with HER2-positive disease).
Study NCT03390608 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: Chemotherapy versus no chemotherapy.
Study NCT03390608 — intervention group
Intervention type: PROCEDURE
Intervention: Type of breast cancer surgery
Description: Type of surgery (partial mastectomy, mastectomy, other).
Study NCT03390608 — intervention group
Intervention type: OTHER
Intervention: Age at diagnosis
Description: Age at diagnosis (\<35, 35-\<50, 50-\<70, ≥70).
Study NCT03390608 — intervention group
Intervention type: OTHER
Intervention: Screen detected tumor
Description: Screening detected tumor (yes, no).
Study NCT03390608 — intervention group
Intervention type: OTHER
Intervention: Menopausal status at diagnosis
Description: Menopausal status (premenopausal, postmenopausal).
Study NCT03390608 — intervention group
Intervention type: OTHER
Intervention: Tumor size
Description: Tumor size (≤5 mm, 6-≤10 mm).
Study NCT03390608 — intervention group
Intervention type: OTHER
Intervention: Estrogen receptor (ER) status
Description: ER-status (positive, negative).
Study NCT03390608 — intervention group
Intervention type: OTHER
Intervention: Tumor grade
Description: Tumor grade (1, 2, 3).
Study NCT03390608 — intervention group
Intervention type: OTHER
Intervention: HER2-status
Description: HER2-status (positive, negative).
Study NCT03390608 — intervention group
Intervention type: OTHER
Intervention: Intrinsic subgroups of breast cancer
Description: Intrinsic subgroup proxy (Luminal A, Luminal B (HER2-negative), Luminal B (HER2-positive), HER2-positive (non-luminal), Triple negative).
Study NCT03624049 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Community based exercise programs held 2-3 times per week
Study NCT03624049 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Health Class
Description: Community based health class held 1 time per week
Study NCT01461096 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV Vaccine
Description: Participants were prescribed one intramuscular (IM) injection of the quadrivalent HPV vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
Study NCT01461096 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine for Male Participants Only
Description: Participants were prescribed one IM injection of the placebo vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
Study NCT01461096 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine for Female Participants Only
Description: Participants were prescribed one IM injection of the placebo vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
Study NCT02679586 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diffusion weighted MRI
Study NCT04316624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-CAR066
Description: Autologous 2nd generation CD20-directed CAR-T cells, single infusion intravenously
Study NCT03869125 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood pressure measurement
Description: Blood pressure monitoring using automated office blood pressure measurement (AOBPM), office blood pressure measurement (OBPM), and 24-hour ambulatory blood pressure monitoring
Study NCT03700359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Anlotinib: Maintenance therapy 12mg/day P.O., day 1-15 every 21 days (2 weeks on, 1 week off) until progressive disease or treatment discontinuation
Study NCT03700359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobaplatin
Description: Lobaplatin:30 mg/m2 IV every 21 days for up to 4 cycles of 21 days
Study NCT03700359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lobaplatin
Description: Lobaplatin:30 mg/m2 IV every 21 days for up to 4 cycles of 21 days
Study NCT03700359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide: 60 mg/m2 IV every 21 days for up to 4 cycles of 21 days
Study NCT03700359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide: 60 mg/m2 IV every 21 days for up to 4 cycles of 21 days
Study NCT00414050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified Process Hepatitis B Vaccine (Experimental)
Description: Modified Process Hepatitis B Vaccine given intramuscularly (IM) in 3 injections of 5 ug (micrograms)/0.5 mL each over 4 months (Modified Process Hepatitis B vaccine 5 μg arm). Modified Process Hepatitis B Vaccine given IM in 3 Injections of 10 ug (micrograms)/0.5 mL each over 4 months (Modified Process Hepatitis B vaccine 10 μg arm).
Study NCT01842516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 800mg
Description: LCB0-0371 800mg
Study NCT01842516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 1200mg
Description: LCB01-0371 1200mg
Study NCT01842516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01652482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: Standard 5-fluorouracil (5-FU) chemotherapy (400 milligram per square meter \[mg/m\^2\] administered as intravenous bolus and then 5-FU 2400 mg/m\^2 administered as continuous intravenous infusion over 46 +/- 2 hours) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
Study NCT01652482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Standard 5-fluorouracil (5-FU) chemotherapy (400 milligram per square meter \[mg/m\^2\] administered as intravenous bolus and then 5-FU 2400 mg/m\^2 administered as continuous intravenous infusion over 46 +/- 2 hours) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
Study NCT01652482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab 400 mg/m\^2 intravenous infusion as a loading dose on Day 1 Cycle 1, followed by 250 mg/m\^2 intravenous infusion weekly until documented disease progression or unacceptable toxicity.
Study NCT01652482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Standard Irinotecan chemotherapy (180 milligram per square meter \[mg/m\^2\] administered as intravenous infusion over 60 +/- 30 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
Study NCT01652482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Standard Irinotecan chemotherapy (180 milligram per square meter \[mg/m\^2\] administered as intravenous infusion over 60 +/- 30 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
Study NCT01652482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Standard Leucovorin chemotherapy (400 mg/m\^2 \[racemic form\] or 200 mg/m\^2 \[L-isomer form\] administered by intravenous infusion over 120 +/- 10 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
Study NCT01652482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Standard Leucovorin chemotherapy (400 mg/m\^2 \[racemic form\] or 200 mg/m\^2 \[L-isomer form\] administered by intravenous infusion over 120 +/- 10 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
Study NCT01652482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEHD7945A
Description: MEHD7945A 1100 milligram (mg) intravenous infusion every 2 weeks until documented disease progression or unacceptable toxicity.
Study NCT00414050 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B Vaccine (Recombinant)
Description: RECOMBIVAX HB™ (currently licensed product) given IM in 3 Injections of 5 ug/0.5 mL each over 4 months.
Study NCT00414050 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B Vaccine (Recombinant)
Description: ENGERIX-B® (currently licensed product) given IM in 3 Injections of 10 ug/0.5 mL each over 4 months
Study NCT03390608 — intervention group
Intervention type: OTHER
Intervention: Nodal status
Description: N-status (N0, N1).
Study NCT01961986 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TSR - traditional subscapularis release
Description: Total Shoulder Replacement surgery performed using the traditional subscapularis release approach.
Study NCT02268097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing with freehand technique
Description: Preparing patellar resurfacing during total knee arthroplasty with freehand
Study NCT02268097 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patellar resurfacing with resection guide technique
Description: Preparing patellar resurfacing during total knee arthroplasty with a resection guide
Study NCT00720876 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Rituximab will be administered at a dose of 375 mg/m2 on day 1 of every cycle, every 3 weeks.
Study NCT00720876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: 200 mg twice daily, orally for 14 days followed by a seven day break on a 21 day cycle.
Study NCT02057107 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: SBRT
Description: 8.8-10 Gy per fraction (total: 44-50 Gy)
Study NCT02057107 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cetuximab
Description: Day -7 (One week prior to commencement of stereotactic radiosurgery):~Cetuximab, 400 mg/m2~Days 0 and 8 (The 1st and 2nd week of radiosurgery):~Cetuximab, 250 mg/m2 Cetuximab, 250 mg/m2 will be given weekly ( following radiosurgery)